WO2025004009 - COMPOSITIONS COMPRISING ISOLATED ENDOTHELIAL PROGENITOR CELLS AND USES THEREOF
National phase entry is expected:
Publication Number
WO/2025/004009
Publication Date
02.01.2025
International Application No.
PCT/IB2024/056371
International Filing Date
28.06.2024
Title **
[English]
COMPOSITIONS COMPRISING ISOLATED ENDOTHELIAL PROGENITOR CELLS AND USES THEREOF
[French]
COMPOSITIONS CONTENANT DES CELLULES PROGÉNITRICES ENDOTHÉLIALES ISOLÉES ET LEURS UTILISATIONS
Applicants **
THE UNIVERSITY OF QUEENSLAND
Inventors
COLDITZ, Paul
KHOSROTEHRANI, Kiarash
KAUR, Simranpreet
Priority Data
2309945.0
29.06.2023
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP Australia
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 6272 | |
| EPO | Filing, Examination, Granting | 117502 | |
| Japan | Filing, Examination, Granting | 5067 | |
| South Korea | Filing, Examination, Granting | 9094 | |
| USA | Filing, Examination, Granting | 38890 |
Total:
176,825
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present technology comprises isolated endothelial progenitor cell (EPC) populations comprising PROCR+/- PDGFRA+/- EPCs and mesenchymal stem cell (MSC) populations, and methods of making and use thereof in treating hypoxic-ischemic encephalopathy (HIE) or brain injury in a subject.[French]
La présente technologie concerne des populations de cellules progénitrices endothéliales (EPC) isolées contenant des populations d'EPC PROCR+ PDGFRA+ et des populations de cellules souches mésenchymateuses (MSC), ainsi que des méthodes de fabrication et d'utilisation de celles-ci pour traiter une encéphalopathie hypoxique-ischémique (HIE) ou une lésion cérébrale chez un sujet.